Annual Working Capital
$422.04 M
-$53.06 M-11.17%
31 December 2023
Summary:
Allogene Therapeutics annual working capital is currently $422.04 million, with the most recent change of -$53.06 million (-11.17%) on 31 December 2023. During the last 3 years, it has fallen by -$328.77 million (-43.79%). ALLO annual working capital is now -43.79% below its all-time high of $750.81 million, reached on 31 December 2020.ALLO Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Working Capital
$271.84 M
-$147.97 M-35.25%
30 September 2024
Summary:
Allogene Therapeutics quarterly working capital is currently $271.84 million, with the most recent change of -$147.97 million (-35.25%) on 30 September 2024. Over the past year, it has dropped by -$163.97 million (-37.62%). ALLO quarterly working capital is now -68.71% below its all-time high of $868.68 million, reached on 30 June 2020.ALLO Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALLO Working Capital Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -11.2% | -37.6% |
| 3 y3 years | -43.8% | -39.5% |
| 5 y5 years | -3.8% | -42.9% |
ALLO Working Capital High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -43.8% | at low | -47.7% | at low |
| 5 y | 5 years | -43.8% | at low | -68.7% | at low |
| alltime | all time | -43.8% | >+9999.0% | -68.7% | +209.3% |
Allogene Therapeutics Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $271.84 M(-35.2%) |
| June 2024 | - | $419.82 M(+15.2%) |
| Mar 2024 | - | $364.47 M(-13.6%) |
| Dec 2023 | $422.04 M(-11.2%) | $422.04 M(-3.2%) |
| Sept 2023 | - | $435.82 M(-2.6%) |
| June 2023 | - | $447.38 M(+6.0%) |
| Mar 2023 | - | $421.88 M(-11.2%) |
| Dec 2022 | $475.10 M(+12.2%) | $475.10 M(-8.7%) |
| Sept 2022 | - | $520.19 M(+11.1%) |
| June 2022 | - | $468.12 M(+8.1%) |
| Mar 2022 | - | $432.87 M(+2.2%) |
| Dec 2021 | $423.42 M | $423.42 M(-5.8%) |
| Sept 2021 | - | $449.37 M(-19.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2021 | - | $556.17 M(-15.9%) |
| Mar 2021 | - | $661.21 M(-11.9%) |
| Dec 2020 | $750.81 M(+46.8%) | $750.81 M(-6.6%) |
| Sept 2020 | - | $803.93 M(-7.5%) |
| June 2020 | - | $868.68 M(+81.9%) |
| Mar 2020 | - | $477.60 M(-6.6%) |
| Dec 2019 | $511.50 M(+16.6%) | $511.50 M(+7.4%) |
| Sept 2019 | - | $476.40 M(+0.6%) |
| June 2019 | - | $473.54 M(+5.4%) |
| Mar 2019 | - | $449.36 M(+2.5%) |
| Dec 2018 | $438.52 M(<-9900.0%) | $438.52 M(+399.0%) |
| Sept 2018 | - | $87.88 M(-68.6%) |
| June 2018 | - | $279.52 M |
| Dec 2017 | -$2000.00 | - |
FAQ
- What is Allogene Therapeutics annual working capital?
- What is the all time high annual working capital for Allogene Therapeutics?
- What is Allogene Therapeutics annual working capital year-on-year change?
- What is Allogene Therapeutics quarterly working capital?
- What is the all time high quarterly working capital for Allogene Therapeutics?
- What is Allogene Therapeutics quarterly working capital year-on-year change?
What is Allogene Therapeutics annual working capital?
The current annual working capital of ALLO is $422.04 M
What is the all time high annual working capital for Allogene Therapeutics?
Allogene Therapeutics all-time high annual working capital is $750.81 M
What is Allogene Therapeutics annual working capital year-on-year change?
Over the past year, ALLO annual working capital has changed by -$53.06 M (-11.17%)
What is Allogene Therapeutics quarterly working capital?
The current quarterly working capital of ALLO is $271.84 M
What is the all time high quarterly working capital for Allogene Therapeutics?
Allogene Therapeutics all-time high quarterly working capital is $868.68 M
What is Allogene Therapeutics quarterly working capital year-on-year change?
Over the past year, ALLO quarterly working capital has changed by -$163.97 M (-37.62%)